Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.88 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5253570 | 0.98 | ADRB1 (0.85) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL5246531 | 0.98 | ADRB1 (0.85) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL177715 | 0.94 | ADRB1 (1.00) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL679616 | 0.92 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL9466563 | 0.92 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL29438749 | 0.92 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL31235563 | 0.92 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL1651102 | 0.91 | ADRB1 (0.94) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL27615104 | 0.84 | ADRB1 (0.81) | ADRB1DRD2DRD1HTR2ADRD3 | |
| SCHEMBL6266386 | 0.84 | ADRB1 (0.77) | ADRB1DRD2DRD1HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-1828125-B1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET SOC CIV (FR) | 2008-04-09 | — | — | EP | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1674103-A1 | Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands | Cepa Schwarz Pharma s.l. (ES) | 2006-06-28 | — | — | EP | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| CN-1564820-A | Heterocyclic compounds for use in the treatment of disorders of the urinary tract | RECORDATI CHEM PHARM (CH) | 2005-01-12 | — | — | CN | disclosed |
| EP-1337528-B1 | BENZOTHIOPHENE DERIVATIVE COMPOUNDS, PROCESS OF PREPARATION AND USE THEREOF | VITA LAB (ES) | 2004-08-04 | — | — | EP | disclosed |
| US-20040034219-A1 | Benzothiophene derivative compounds process of preparation and use thereof | LABORATORIOS VITA, S.A. (ES) | 2004-02-19 | — | — | US | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| US-4833142-A | Blood-pressure lowering 4-bicyclic-1-piperazinyl-alkyl amides | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1989-05-23 | — | — | US | disclosed |
| EP-0138280-B1 | BLOOD-PRESSURE LOWERING PIPERAZINE DERIVATIVES | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1988-06-08 | — | — | EP | disclosed |
| EP-0138280-A2 | Blood-pressure lowering piperazine derivatives | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | ADRB1 28/4885DRD2 163/4885DRD1 133/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | ADRB1 371/4885DRD2 2/4885DRD1 1/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | ADRB1 456/4885DRD2 242/4885DRD1 583/4885 |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | ADRB1 61/4885DRD2 214/4885DRD1 293/4885 |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | SLC6A3, ADRB3, PRLHR | ADRB1 29/4885DRD2 8/4885DRD1 49/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | ADRB1 371/4885DRD2 2/4885DRD1 1/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | ADRB1 371/4885DRD2 2/4885DRD1 1/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | ADRB1 28/4885DRD2 85/4885DRD1 54/4885 |
| US-20040034219-A1 | Benzothiophene derivative compounds process of preparation and use thereof | TPH1, HTR1A, HTR5A | ADRB1 82/4885DRD2 123/4885DRD1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.